Browsing Tag
dementia with Lewy bodies
2 posts
Zervimesine development highlights regulatory complexity in dementia with Lewy bodies
Zervimesine moves closer to Phase 2b as Cognition Therapeutics engages FDA. Read how regulatory complexity is shaping dementia drug development.
Cognition Therapeutics reports promising Phase 2 results for CT1812 in dementia with Lewy bodies
Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage pharmaceutical company focused on neurodegenerative disorder treatment, has reported highly encouraging…